Role and side-effects of TPMT polymorphisms of 6-MP and azathioprine in the treatment of steroid-resistant and -dependent ulcerative colitis

Journal of Gastroenterology

Volumn 38, Issue 8, 2003, Pages 806-809

  Asakura, Hitoshi ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; THIOPURINE METHYLTRANSFERASE;

BONE MARROW SUPPRESSION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EDITORIAL; GENETIC POLYMORPHISM; HEPATITIS; HUMAN; IMMUNOPATHOGENESIS; INFECTION; LEUKOPENIA; PANCREATITIS; PANCYTOPENIA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; THROMBOCYTOPENIA; TUMOR; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; AZATHIOPRINE; COLITIS, ULCERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLTRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0141856575     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-003-1165-0     Document Type: Editorial

References (25)

1. Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003;38:740-6.
2. Toms C, Powrie F. Control of intestinal inflammation by regulatory cells. Microbes Infect 2001;3:929-35.
3. Apostolou I, Sorukhan A, Klein L, von Boehner H. Origin of regulatory T cells with known specificity for antigen. Nature Immunol 2002;3:756-63.
4. Funakoshi K, Sugimura K, Anezaki K, Bannai H, Ishizuka K, Asakura H. Spectrum of cytokine gene expression in intestinal mucosal lesions of Crohn's disease and ulcerative colitis. Digestion 1998;59:73-8.
5. Asakura H. Proinflammatory cytokines in IBD. J Gastroenterol 1999;34:149-51.
6. Ishizuka K, Sugimura K, Homma T, Matsuzawa J, Mochizuki T, Kobayashi M, et al. Influence of interleukin-10 on the interleukin-1 receptor antagonist/interleukin-1β ratio in the colonic mucosa of ulcerative colitis. Digestion 2001;63(Supol 1):22-7.
7. Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, et al. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-α for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J Gastroenterol Hepatol 2001;16: 763-9.
8. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001;15:1699-708.
9. Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118:279-88.
10. Schottelius A, Wedel S, Weltrich R, Rohde W, Buttgereit F, Schreiber S, et al. Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease. Am J Gastroenterol 2000;95:1994-9.
11. Flood L, Lofberg R, Stierna P, Wikstrom AC. Glucocorticoid receptor mRNA in patients with ulcerative colitis: a study of responders and nonresponders to glucocorticosteroid therapy. Inflamm Bowel Dis 2001;7:202-9.
12. Honda M, Orii F, Ayabe T, Imai S, Obara T, Kohgo Y. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000;118:859-66.
13. Orii F, Ashida T, Nomura M, Maemoto A, Fujiki T, Ayabe T, et al. Quantitative analysis for human glucocorticoid receptor alpha/beta mRNA in IBD. Biochem Biophys Res Commun 2002; 296:1286-94.
14. Mackay IR, Wall AJ, Goldstein G. Response to azathioprine in ulcerative colitis. Report of 7 cases. Am J Dig Dis 1966;11: 536-45.
15. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975;69:96-9.
16. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-9.
17. Fernandez-Banares F, Bertran X, Esteve-Comas M, Cabre E, Menacho M, Humbert P, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91:2498-509.
18. Present DH, Meltzere SJ, Krumholz MP, Wolke A, Korelitz BL. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and-long term toxicity. Ann Intern Med 1989;111:641-9.
19. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.
20. Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999;94:3248-53.
21. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
22. Cuffari C, Hunt S, Bayless T. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6.
23. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritamce of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
24. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
25. Corominas H, Domenech M, Laiz A, Gich I, Geli C, Diaz C, et al. Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatology 2003;42:40-5.